You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Despite many years of translational research in breast cancer, very few new biomarkers have been implemented for clinical use beyond estrogen receptor, progesterone receptor, and HER2. The main reason is that many promising biomarkers are clinically validated but lack analytical and clinical utility. One explanation is that proper validation of the predictive ability of the biomarker in independent datasets, and with a pre-planned statistical analysis, is not always performed. Thus, there is a need to identify new biomarkers or new ways to subclassify breast cancer patients that are reproducible and easy to implement in the clinical setting but, more importantly, that improve patient’s outcomes.
Praise for the First Edition ÏAs everyone in oncology fellowship training knows, there is a huge [information] gap in this field. Most oncology books are massive and loaded with information÷by the time the book is [published] it is outdated. [Tumor Board Review] is fresh and just out of the oven÷I havenÌt seen any book in oncology like this so far÷I think my investment in this book was wise and worth it. Humaid Al-Shamsi, MB(Hon), BMedSc, MRCP(UK), FRCP, FACP, Assistant Professor, The University of Texas, MD Anderson Cancer Center Culling the knowledge and expertise of respected oncology specialists, this is a concise yet comprehensive review of all areas of oncology practice for medica...
Tumor Board Review utilizes the knowledge and expertise of oncology specialists to enhance learning the practice of oncology. Each of the 32 chapters follows a uniform format: a concise summary of the epidemiology, risk factors, natural history, and pathology of each major organ-specific tumor type an abbreviated display of the relevant staging (generally based on the American Joint Commission on Cancer [AJCC] Staging, 7th Edition) and several œtumor board“style” illustrative patient case summaries (representative of major stage categories of each tumor), each followed by an evidence-based case discussion which reviews the current guidelines and rationale for the diagnostic and therapeu...
Peterson's Graduate Programs in Computational, Systems, & Translational Biology; Ecology, Environmental Biology, & Evolutionary Biology; and Entomology contains a wealth of information on universities that offer graduate/professional degrees in these fields. Up-to-date data, collected through Peterson's Annual Survey of Graduate and Professional Institutions, provides valuable information on degree offerings, professional accreditation, jointly offered degrees, part-time and evening/weekend programs, postbaccalaureate distance degrees, faculty, students, degree requirements, entrance requirements, expenses, financial support, faculty research, and unit head and application contact information. Readers will find helpful links to in-depth descriptions that offer additional detailed information about a specific program or department, faculty members and their research, and much more. In addition, there are valuable articles on financial assistance, the graduate admissions process, advice for international and minority students, and facts about accreditation, with a current list of accrediting agencies.
Stay on top of the latest knowledge in the field with this must-have resource for all clinicians who treat breast diseases. Expand your knowledge of every aspect of breast diseases as a diverse and distinguished group of internationally-recognized experts summarize the current knowledge, including biology and epidemiology, clinical features, and management. Ideal for any clinician seeing patients with breast disease, especially carcinoma of the breast, This full color 5th Edition of the authoritative text in the field is designed to foster the understanding necessary to provide optimal patient care.. Features Covering the latest major clinical trials, along with concise management summaries ...
None
This book analyzes policy fights about what counts as good evidence of safety and effectiveness when it comes to new health care technologies in the United States and what political decisions mean for patients and doctors. Medical technologies often promise to extend and improve quality of life but come with many questions: Are they safe and effective? Are they worth the cost? When should they be allowed on the market, and when should Medicare, Medicaid, and private insurance companies be required to pay for drugs, devices, and diagnostic tests? Using case studies of disputes about the value of mammography screening; genetic testing for disease risk; brain imaging technologies to detect biom...